Finding signs of opioid withdrawal in infants' cries, a malaria vaccine, and gene therapy treatment for post-traumatic osteoarthritis are just a few of the research projects at Brown University that will receive $100,000 to help translate their research into commercial products.
The investment is the second round of funding from Brown Biomedical Innovations to Impact (BBII). The initiative's managing director, Karen Bullock, says the financial support "is to support biomedical technologies that need additional work to become products that have commercialization potential."
Read the story in Brown News to learn more about the initiative.
Brown to fund biomedical technologies with commercial potential, patient benefits